Medindia

X

Starch Medical Launches Novel Plant Sourced Surgical Hemostatic Pad

Wednesday, October 21, 2009 General News J E 4
Advertisement


SAN JOSE, Calif., Oct. 20 Starch Medical Inc (SMI), a San Jose, CA-based medical device manufacturer, announces the first controlled clinical intro/launch of SealFoam(TM) Absorbable Polysaccharide Hemostat in the European Union and other major international markets. Introduction of SealFoam(TM) Absorbable Polysaccharide Hemostat will commence this month at the European Association of Cardio-Thoracic Surgeons congress in Vienna and in November at the MEDICA congress in Dusseldorf, Germany (booth #16E20).

SealFoam(TM) is the latest addition to the Absorbable Modified Polymer (AMP(TM)) product line and offers a hemostatic foam (pad) configuration for a wide range of surgical wounds. The ultra hydrophilic and adhesive properties of SealFoam(TM) are especially formulated to control oozing or profuse bleeding, and to minimize the possibility of re-bleeding. The pad may also be trimmed to suit the surgical procedure and is indicated for a diverse range of applications and unique wound contours.

AMP(TM) technology is a proprietary engineering process that modifies plant starch into biocompatible, absorbable, hemostatic polysaccharide particles. AMP(TM) particles have a molecular structure that rapidly absorbs water from blood, causing a high concentration of platelets, red blood cells and coagulation proteins which accelerate the physiologic clotting cascade at the bleeding site.

David Lang, President of SMI, states "SealFoam(TM) is currently the only available surgical hemostatic pad derived from plant starch without animal/human components. The superb efficacy offers surgeons a safe alternative for achieving hemostasis under various surgical conditions. We will introduce SealFoam(TM) through our global distribution network and potential partners during the 4th quarter of this year."

SMI is a privately-held medical device company engaged in the design, manufacture, marketing and licensing of breakthrough, hemostatic solutions. Starch Medical's proprietary, patent-pending technology platform (AMP(TM)), including powders, foams and films, will focus on the worldwide, multi-billion dollar biomaterial, hemostasis, and wound care marketplace.

For additional information, distribution inquiries, and licensing options, please visit www.starchmedical.com.

Contact: Jane Chen of Starch Medical Inc, +1-408-428-9818, jane@starchmedical.com

SOURCE Starch Medical Inc
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
American Hospital Association (AHA) Names OnBase '...
S
Top 5 Questions Asked by RNs Considering a Bachelo...